Navigation Links
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
Date:11/20/2007

cts, with a focus on pharmaceutical products for the treatment of diseases and consumer products for the maintenance of everyday health. Otsuka is committed to being a corporation that creates global value, adhering to the high ethical standards required of a company involved in human health and life, maintaining a dynamic corporate culture, and working in harmony with local communities and the natural environment. The Otsuka Pharmaceutical Group comprises 99 companies and employs approximately 31,000 people in 17 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned U.S. $7.2 billion in annual revenues in fiscal 2006.

Bristol-Myers Squibb is a global pharmaceutical and related healthcare products company whose mission is to extend and enhance human life.

For more information and FULL PRESCRIBING INFORMATION,

including Boxed WARNING, visit: http://www.abilify.com

Visit Bristol-Myers Squibb at: http://www.bms.com

Visit Otsuka Pharmaceutical Co., Ltd. at: http://www.otsuka-global.com

* Inadequate response for prospective treatment was defined as less than

50 percent improvement on the 17-item version of the Hamilton Depression

Rating Scale (HAMD17), minimal HAMD17 score of 14, and a Clinical Global

Impressions Improvement rating of no better than minimal improvement.

References

(1) Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and Longer-Term

Outcomes in Depressed Outpatients Requiring One or Several Treatment

Steps: A STAR*D Report. Am J Psych. 2006;163:1905-1917.

(2) Kessler RC, Berglund P, Demler O, et al. The epidemiology of major

depressive disorder: results from the national comorbidity survey

replication (NCS-R). JAMA. June 18 2003;289(23):3095-3105.

(3)
'/>"/>

SOURCE Bristol-Myers Squibb Company and Otsuka PharmaceuticalCo., Ltd.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Bioscrypts V-Station MIFARE Placed on Transportation Security Administrations Qualified Products List
3. Australian Therapeutics Goods Administration Approval for ActiPatch Achieved
4. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
5. Korean Food and Drug Administration Approval for ActiPatch Achieved
6. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
7. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
8. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
9. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
10. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
11. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 Sales Horizons, a ... its online sales training course – Mastering the ... sales performance. , Drawn from proven sales training programs ... Mastering the Complex Sale online sales training course is ... who has face-to-face contact with customers, like technical support, ...
(Date:7/30/2014)... 30, 2014 W. R. Grace ... of the REVELERIS® Prep purification system , ... chromatographers, and other researchers to perform both flash ... unit. , With the REVELERIS® Prep purification system, ... chromatography modes with a simple touch of the ...
(Date:7/30/2014)... , July 30, 2014  The Chicago Bears ... American Academy of Dermatology (Academy) in an effort to ... Chicago Bears will host free SPOT me™ skin cancer ... 2 at Soldier Field. SPOT me™ is an ... about the dangers and risks of skin cancer, and ...
(Date:7/30/2014)... Selexis SA , a serial innovation company ... cell line development, announced today new data from the ... at the 10th Annual Cell Line Development and ... 2014 at the Double Tree by Hilton Berkeley Marina ... be presented during an oral presentation: , Title: Genome ...
Breaking Biology Technology:Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 2Sales Horizons Offers Mastering the Complex Sale - a Comprehensive, Online Sales Skills Training Course 3Grace Launches New REVELERIS® Prep Purification System 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3
... Diseases and,Disorders, OLDSMAR, Fla., Jan. 29 ... ("Cryo-Cell" or the "Company"), one of the,largest ... today announced that,it has formalized a research ... ("Saneron") that represents an important milestone in,efforts ...
... RESEARCH TRIANGLE PARK, N.C., Jan. 29 ,Merial Limited and ... under which Merial will screen a Chimerix chemical library ... agreement, Merial has an,option to negotiate a license with ... "This collaboration with Chimerix provides us with an opportunity ...
... year end; no equity financings expected in 2008, ... continue in,2008; latest data for all programs to be ... Expansion of research and development investment in pharmacological, ... 2008, CRANBURY, N.J., Jan. 29 Amicus Therapeutics,(Nasdaq: ...
Cached Biology Technology:Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc. 2Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc. 3Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc. 4Merial to Screen Chimerix' Chemical Library for Animal Health Drug Leads 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 3Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 4Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 5Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 6Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 7Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 8Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 9Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 10Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 11Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 12Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 13Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 14
(Date:7/30/2014)... simple as inserting a medicated, disappearing fabric minutes before ... discovered a potentially faster way to deliver a topical ... spins the drug into silk-like fibers that quickly dissolve ... the drug than possible with other topical materials such ... a potentially more effective, discreet way to protect themselves ...
(Date:7/30/2014)... NexID Biometrics , a leading ... for the biometric authentication industry, has recently joined ... authentication with standards for strong authentication. According to ... to join FIDO Alliance stems from NexID,s mission ... We believe the FIDO Alliance is a key ...
(Date:7/30/2014)... Press Limited today announced an across-the-board increase in ... The 2013 InCites Journal Citation Reports (Thomson Reuters, ... Biochemical Journal , Essays in Biochemistry , ... Reports all received increases in their Impact ... Society and published by Portland Press Limited. , ...
Breaking Biology News(10 mins):Dissolvable fabric loaded with medicine might offer faster protection against HIV 2Dissolvable fabric loaded with medicine might offer faster protection against HIV 3NexID Biometrics Joins the FIDO Alliance 2Across-the-board Impact Factor increases for Portland Press Limited 2
... enhance threat and radiation detection, improve life sciences ... received recognition for their innovation today. R&D Magazine ... Department of Energy,s Pacific Northwest National Laboratory with ... selects the 100 most innovative scientific and technological ...
... KINGSTON, R.I. July 8, 2010 A new ... been developed by a team of University of Rhode ... that can be triggered by non-invasive electromagnetic fields. ... Bose and graduate student Yanjing Chen was published in ...
... (July 8, 2010) By solving the three-dimensional structure ... group of McMaster University researchers have revealed new avenues ... living with hereditary colorectal cancers. The finding, published ... important step forward in the field of molecular and ...
Cached Biology News:PNNL scientists win 4 R&D 100 awards for environment, biology, security technologies 2PNNL scientists win 4 R&D 100 awards for environment, biology, security technologies 3PNNL scientists win 4 R&D 100 awards for environment, biology, security technologies 4PNNL scientists win 4 R&D 100 awards for environment, biology, security technologies 5Researchers develop drug delivery system using nanoparticles triggered by electromagnetic field 2DNA discovery opens new door to develop tools, therapies for hereditary cancers 2